Ready for takeoff

Here's how to watch the historic NASA/SpaceX mission launch in Houston

Houston-area NASA astronauts Robert Behnken and Douglas Hurley will make a historic flight. Photo courtesy of NASA

Update: The launch was scrubbed a few minutes before launch due to undesirable weather conditions. The new launch date is Saturday, May 30, at around 2:30 CST. The original story is below.

Two Houston-area NASA astronauts are set to make history. Robert Behnken and Douglas Hurley will blast off on Elon Musk's SpaceX's Crew Dragon spacecraft, a Falcon 9 rocket, at 3:33 pm (CST) Wednesday, May 27, from the Kennedy Space Center in Cape Canaveral, Florida.

The flight is currently scheduled as a 60-percent "go" for launch as of May 27, with only inclement weather or a technical issue holding up the takeoff. Due to COVID-19 and subsequent social distancing issue, the launch will see only a small crowd at the Cape Canaveral takeoff.

The mission will carry the duo to the International Space Station and is considered a new era of human spaceflight, as American astronauts will once again launch on an American rocket from American soil to low-Earth orbit for the first time since the conclusion of the Space Shuttle Program in 2011, according to NASA.

NASA's SpaceX Demo-2 mission is the first launch with astronauts of the SpaceX Crew Dragon spacecraft and Falcon 9 rocket to the International Space Station as part of the agency's Commercial Crew Program. It's the final flight test for SpaceX; the mission will validate the company's crew transportation system, including the launch pad, rocket, spacecraft, and operational capabilities.

This also will be the first time NASA astronauts will test the spacecraft systems in orbit — Behnken and Hurley will don new, specially designed spacesuits and use touchscreen computers systems. The pairing of NASA — a governmental agency — and SpaceX, a commercial space flight operation, means NASA could save tens of millions in flight costs and instead focus on its Artemis mission to the moon, for example.

"The ultimate goal for us as astronauts and test pilots is just to go up there and prove out the mission and to bring the vehicle home safely," Hurley told CultureMap news partner, ABC13.

Proud Houstonians can watch NASA's coverage, which began at 11:15 am Wednesday, May 27, and will run through the Crew Dragon's docking at the International Space Station on Thursday, May 28. Expect a hatch opening and welcoming ceremony.

As part of the pre-launch ceremonies, at 12:07 pm, Burleson, Texas native Kelly Clarkson sang the National Anthem.

A special called Space Launch Live: America Returns to Space airs at 1 pm on the Discovery and Science Channel and will feature special celebrity guests including singer Katy Perry, Adam Savage, former NASA engineer and YouTube star Mark Robert, and astronaut Chris Cassidy from the International Space Station.

Meanwhile, launch and prelaunch activities on YouTube, Twitter, Facebook, and even Linkedin. For those watching at home and looking for a festive theme, Space Center Houston created an at-home viewing guide, including a playlist, outfits, and space food.

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News